Consequences of meta-stable ^177mLu admixture in ¹⁷⁷Lu for patient dosimetry

E-ISSN： 1874-4729|8|2|145-149

ISSN： 1874-4710

Source： Current Radiopharmaceuticals, Vol.8, Iss.2, 2015-08, pp. : 145-149

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Lutetium-177 (lt;supgt;177lt;/supgt;Lu) is a rare earth metal in the lanthanides series which decays by betaemission with a half life of 6.647 days to three excited states and the ground state of lt;supgt;177lt;/supgt;Hf. Whenlt;supgt;177lt;/supgt;Lu is produced by neutron capture in lt;supgt;176lt;/supgt;Lu, inevitably an admixture is formed of the long-livedisomer lt;supgt;177lt;/supgt;mLu. As its half-life of 160.4 days is so much longer than that of lt;supgt;177lt;/supgt;Lu, concerns are raisedon its possible enhancement in radiation dose to the patient treated with lt;supgt;177lt;/supgt;Lu-DOTA-octreotate. Thisreport evaluates this possible enhancement of the absorbed dose, based on the published pharmacokineticprofile of lt;supgt;177lt;/supgt;Lu-DOTA-octreotate and assuming an admixture of 1 kBq lt;supgt;177lt;/supgt;mLu /MBq lt;supgt;177lt;/supgt;Lu(0.1%).